Predictive value of serum prolactin levels measured immediately after transsphenoidal surgery

Journal of Neurosurgery

Volumn 97, Issue 2, 2002, Pages 307-314

  Amar, Arun P ^a   Couldwell, William T ^a   Chen, Joseph C T ^a   Weiss, Martin H ^a  

^a NONE   (United States)

Author keywords

Pituitary adenoma; Prolactin; Prolactinoma transsphenoidal approach

Indexed keywords

ADOLESCENT; ADULT; ARTICLE; CHILD; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; HYPOPHYSIS ADENOMA; MAJOR CLINICAL STUDY; MALE; NEUROSURGERY; POSTOPERATIVE PERIOD; PREDICTION; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROGNOSIS; PROLACTIN BLOOD LEVEL; PROLACTINOMA; REOPERATION; TREATMENT OUTCOME; TUMOR RECURRENCE; TUMOR VOLUME;

EID: 0036329428     PISSN: 00223085     EISSN: None     Source Type: Journal    
DOI: 10.3171/jns.2002.97.2.0307     Document Type: Article

References (65)

1. Discordant responses of prolactinoma to two different dopamine agonists
2. Prolactinomas: Focus on indications, outcomes, and management of recurrences
3. Endocrine outcome after transsphenoidal adenomectomy for prolactinoma: Prolactin levels and tumor size as predicting factors
4. Continued growth of a large pituitary prolactinoma despite high dose bromocriptine
5. Cabergoline: An advance in dopaminergic therapy
6. Dopamine agonists and pituitary tumor shrinkage
7. Failure of bromocriptine to maintain reduction in size of a macroprolactinoma
8. Long-term follow-up results in hormonally active pituitary adenomas after primary successful transsphenoidal surgery
9. Surgical treatment of prolactinomas. Short- and long-term results, prognostic factors
10. Long-term treatment with cabergoline, a new long-lasting ergoline derivative, in idiopathic or tumorous hyperprolactinaemia and outcome of drug-induced pregnancy
11. The transnasal transsphenoidal approach
12. Enlargement of a prolactin-secreting pituitary microadenoma during bromocriptine treatment. Case report
13. The effect of quinagolide and cabergoline, two selective dopamine receptor type 2 agonists, in the treatment of prolactinomas
14. Short-term preoperative treatment of macroprolactinomas by dopamine agonists
15. Transsphenoidal pituitary resection for preoperative diagnosis of prolactin-secreting pituitary adenoma in women: Long term follow-up
16. Surgical results in microadenomas
17. Enlarged adenomectomy for enclosed prolactinomas: A preliminary study of 26 cases
18. An ultrarapid prognostic index in microprolactinoma surgery
19. Prolactin-secreting adenomas: The preoperative response to bromocriptine treatment and surgical outcome
20. Decreased bone density in hyperprolactinemic women
21. Surgical management of growth hormone-secreting and prolactin-secreting pituitary adenomas
22. Growth of prolactinoma despite lowering of serum prolactin by bromocriptine
23. Visual loss in pregnant women with pituitary adenomas
24. Surgical treatment of pituitary prolactinomas: Post-operative prolactin and fertility in seventy patients
25. Gamma knife radiosurgery for prolactinomas
26. Comment on Tyrrell JB, Lamborn KR, Hannegan LT, et al: Transsphenoidal microsurgical therapy of prolactinomas: Initial outcomes and long-term results
27. Prolactin-secreting adenomas: Surgical results and long-term follow-up
28. Longitudinal evaluation of patients with untreated prolactin-secreting pituitary adenomas
29. Transsphenoidal adenomectomy for microprolactinomas: 10 To 20 years of follow-up
30. Management of prolactinomas during pregnancy
31. Pathologic hyperprolactinemia
32. Use of cabergoline in the long-term treatment of hyperprolactinemic and acromegalic patients
33. Management of prolactin-secreting pituitary adenomas
34. Pituitary disorders. Drug treatment options
35. Prolactin-secreting pituitary adenomas: Analysis of 429 surgically treated patients, effect of adjuvant treament modalities and review of the literature
36. Gamma knife radiosurgery as a primary treatment for prolactinomas
37. Resistance to bromocriptine in prolactinomas
38. Cabergoline. A review of its pharmacological properties and therapeutic potential in the treatment of hyperprolactinaemia and inhibition of lactation
39. Long-term follow-up of transsphenoidal selective adenomectomy for prolactinoma
40. Prolactin reduction after combined therapy for prolactin macroadenomas
41. The natural history of untreated hyperprolactinemia: A prospective analysis
42. Long term follow-up of women with surgically treated prolactin-secreting pituitary tumors
43. Progress in the managment of hyperprolactinemia
44. Relapse of hyperprolactinemia revisited
45. Recurrence of hyperprolactinemia after selective transsphenoidal adenomectomy in women with prolactinoma
46. Management of pituitary tumors
47. Implications of very high serum prolactin levels associated with pituitary tumors
48. Comment on Tyrrell JB, Lamborn KR, Hannegan LT, et al: Transsphenoidal microsurgical therapy of prolactinomas: Initial outcomes and long-term results
49. The natural history of untreated microprolactinomas
50. Ten year follow up of microprolactinoma treated by transsphenoidal surgery
51. Relapse of hyperprolactinemia after transsphenoidal surgery for microprolactinoma: Lessons from long-term follow-up
52. Long-term follow-up of 246 hyperprolactinemic patients
53. Transsphenoidal microsurgical therapy of prolactionmas: Initial outcomes and long-term results
54. Prolactinomas
55. Low recurrence rate after partial hypophysectomy for prolactinoma: The predictive value of dynamic prolactin function tests
56. A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea
57. Medical and surgical management of functional pituitary tumors
58. Pituitary tumors: An endocrinological and neurosurgical challenge
59. Treatment options in the management of prolactin-secreting pituitary tumors
60. Natural history of microprolactinomas: Six-year follow-up
61. Bromocriptine treatment of prolactin-secreting tumors: Surgical implications
62. A decade of pituitary microsurgery. The Herbert Olivecrona lecture
63. Surgical management of pituitary tumors
64. Indications for surgery in the treatment of hyperprolactinemia